3028770-95-5
Chemical Structure
W1307
- CAS No.: 3028770-95-5
- Formula:C20H15N3O3
- Molecular Weight:345.35
InChIKey: BTVGDVWRBADADA-UHFFFAOYSA-N
SMILES: COC1=CC=C2C(N=C(C3=CC=CC=C3)C=C2C(NC4=NC=CO4)=O)=C1
Biological Activity: W1307 is a selective STAT3 inhibitor with a KD value of 1.74 μM. W1307 inhibits STAT3 Tyr705 phosphorylation, disrupts STAT3 dimerization, and suppresses STAT3 transcriptional activity. W1307 downregulates the expression of STAT3 downstream targets c-Myc, Mcl-1 and Bcl-2. W1307 transcriptionally inhibits SREBP1 and CPT2 expression to disrupt lipid homeostasis. W1307 shows potent anti-leukemic activity and synergizes with Cytarabine (Ara-C) (HY-13605) to overcome chemoresistance in acute myeloid leukemia (AML)[1].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
W1307 | W1307 is a selective STAT3 inhibitor with a KD value of 1.74 μM. W1307 inhibits STAT3 Tyr705 phosphorylation, disrupts STAT3 dimerization, and suppresses STAT3 transcriptional activity. W1307 downregulates the expression of STAT3 downstream targets c-Myc, Mcl-1 and Bcl-2. W1307 transcriptionally inhibits SREBP1 and CPT2 expression to disrupt lipid homeostasis. W1307 shows potent anti-leukemic activity and synergizes with Cytarabine (Ara-C) (HY-13605) to overcome chemoresistance in acute myeloid leukemia (AML). | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
